<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE ArticleSet PUBLIC "-//NLM//DTD PubMed 2.7//EN" "https://dtd.nlm.nih.gov/ncbi/pubmed/in/PubMed.dtd">
<ArticleSet>
<Article>
<Journal>
				<PublisherName>West Asia Organization for Cancer Prevention (WAOCP), APOCP's West Asia Chapter.</PublisherName>
				<JournalTitle>Asian Pacific Journal of Cancer Prevention</JournalTitle>
				<Issn>1513-7368</Issn>
				<Volume>15</Volume>
				<Issue>6</Issue>
				<PubDate PubStatus="epublish">
					<Year>2014</Year>
					<Month>06</Month>
					<Day>01</Day>
				</PubDate>
			</Journal>
<ArticleTitle>Triple Negative Breast Cancer</ArticleTitle>
<VernacularTitle></VernacularTitle>
			<FirstPage>2427</FirstPage>
			<LastPage>2431</LastPage>
			<ELocationID EIdType="pii">28936</ELocationID>
			
			
			<Language>EN</Language>
<AuthorList>
</AuthorList>
				<PublicationType>Journal Article</PublicationType>
			<History>
				<PubDate PubStatus="received">
					<Year>1970</Year>
					<Month>01</Month>
					<Day>01</Day>
				</PubDate>
			</History>
		<Abstract>Triple-negative breast cancers (TNBC), characterized by absence of the estrogen receptor (ER) andprogesterone receptor (PR) and lack of overexpression of human epidermal growth factor receptor 2 (HER2),have a poor prognosis. To overcome therapy limitations of TNBC, various new approaches are needed. Thismini-review focuses on discovery of new targets and drugs which might offer new hope for TNBC patients.</Abstract>
		<ObjectList>
			<Object Type="keyword">
			<Param Name="value">triple negative breast cancer</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">poor prognosis</Param>
			</Object>
			<Object Type="keyword">
			<Param Name="value">targeted therapy</Param>
			</Object>
		</ObjectList>
<ArchiveCopySource DocType="pdf">https://journal.waocp.org/article_28936_81eb35213e361297755f98ca168b61ca.pdf</ArchiveCopySource>
</Article>
</ArticleSet>
